Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clini
![Diagnostics | Free Full-Text | miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction—Added Value over Left Ventricular Myocardial Work Diagnostics | Free Full-Text | miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction—Added Value over Left Ventricular Myocardial Work](https://www.mdpi.com/diagnostics/diagnostics-12-01946/article_deploy/html/images/diagnostics-12-01946-g004.png)
Diagnostics | Free Full-Text | miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction—Added Value over Left Ventricular Myocardial Work
![A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease - Evans - 2021 - A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease - Evans - 2021 -](https://onlinelibrary.wiley.com/cms/asset/1ee41962-3008-4c55-b068-203fe25885fa/edm2259-toc-0001-m.jpg?trick=1691999674972)
A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease - Evans - 2021 -
![Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high ... Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high ...](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12933-018-0682-3/MediaObjects/12933_2018_682_Fig3_HTML.gif)
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high ...
![Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. - Abstract - Europe PMC Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. - Abstract - Europe PMC](https://europepmc.org/articles/PMC9351217/bin/12933_2022_1575_Fig4_HTML.jpg)
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. - Abstract - Europe PMC
![Study flow chart. (Abbreviation: 3P-MACE, three point major adverse... | Download Scientific Diagram Study flow chart. (Abbreviation: 3P-MACE, three point major adverse... | Download Scientific Diagram](https://www.researchgate.net/publication/368565883/figure/fig1/AS:11431281120575536@1676559295181/Study-flow-chart-Abbreviation-3P-MACE-three-point-major-adverse-cardiovascular-event.png)
Study flow chart. (Abbreviation: 3P-MACE, three point major adverse... | Download Scientific Diagram
![Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials | Cardiovascular Diabetology | Full Text Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-020-01034-3/MediaObjects/12933_2020_1034_Fig2_HTML.png)
Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials | Cardiovascular Diabetology | Full Text
Expert Cross Talk | Lupin India | Topic: Approach of Screening Cardiovascular Risk in T2DM Speaker: Dr. Abhamoni Baro and Dr. Chandan Modak Disclaimer: This program is facilitated by... | By Lupin India | Facebook
![3P-MACE by baseline covariates. The Forest plot shows hazard ratios... | Download Scientific Diagram 3P-MACE by baseline covariates. The Forest plot shows hazard ratios... | Download Scientific Diagram](https://www.researchgate.net/publication/356191073/figure/fig5/AS:1089912682094594@1636866841171/3P-MACE-by-baseline-covariates-The-Forest-plot-shows-hazard-ratios-HR-and-95.png)
3P-MACE by baseline covariates. The Forest plot shows hazard ratios... | Download Scientific Diagram
![Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes | Cardiovascular Diabetology | Full Text Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-022-01651-0/MediaObjects/12933_2022_1651_Fig1_HTML.png)
Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes | Cardiovascular Diabetology | Full Text
![Abbreviations 3P-MACE: 3-point major adverse cardiovascular events;... | Download Scientific Diagram Abbreviations 3P-MACE: 3-point major adverse cardiovascular events;... | Download Scientific Diagram](https://www.researchgate.net/profile/Hans-Juergen-Woerle/publication/263289771/figure/fig2/AS:669628678295552@1536663326016/Abbreviations-3P-MACE-3-point-major-adverse-cardiovascular-events-4P-MACE-4-point_Q320.jpg)
Abbreviations 3P-MACE: 3-point major adverse cardiovascular events;... | Download Scientific Diagram
![Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED‐J Study | Journal of the American Heart Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED‐J Study | Journal of the American Heart](https://www.ahajournals.org/cms/asset/9653c105-814e-41ff-b2bd-42d89846996a/jah37018-fig-0001.png)
Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED‐J Study | Journal of the American Heart
![Alfonso Valle on X: "Efficacy & safety of SGLT2i/GLP-1RA for CV outcomes: meta-analysis 👥 170930 👉GLP-1RA & SGLT2i ⤵️11% 3P-MACE vs placebo/DPP-4 👉SGLT2i vs GLP-1RA ⛔️difference in 3P-MACE SGLT2i ⤵️ 24% HF🏥 Alfonso Valle on X: "Efficacy & safety of SGLT2i/GLP-1RA for CV outcomes: meta-analysis 👥 170930 👉GLP-1RA & SGLT2i ⤵️11% 3P-MACE vs placebo/DPP-4 👉SGLT2i vs GLP-1RA ⛔️difference in 3P-MACE SGLT2i ⤵️ 24% HF🏥](https://pbs.twimg.com/media/E_qUz8bWYAQPFUK.jpg)